JERUSALEM Biocanell Therapeutics has announced its successful results of a clinical trial of its BC-819 treatment for ovarian cancer, according to published reports.
The company reported a 50 percent reduction in the protein marker that indicates the presence of ovarian cancer and a significant decline in the number of cancer cells in patients.
BC-819 is intended for patients for whom conventional ovarian cancer treatments have failed. Biocancell said that the drug is an important breakthrough in cancer treatments. The drug is also intended to treat cancer in the liver, bladder and spleen, all of which are expressions of the H-19 gene.